This inventor holds 1 USPTO granted patent. Top assignees: Hadasit Medical Research Services and Development Ltd., Technion Research & Development Foundation Ltd. Active years: 2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:

Years Active: 2021
Title: Marina Weissmann: Innovator in Heparanase-Neutralizing Monoclonal Antibodies
Introduction
Marina Weissmann is a prominent inventor based in Netanya, Israel. She has made significant contributions to the field of biomedical research, particularly in the development of heparanase-neutralizing monoclonal antibodies. Her work has the potential to impact various diseases associated with heparanase activity.
Latest Patents
Marina Weissmann holds 1 patent for her invention titled "Heparanase-neutralizing monoclonal antibodies." This invention relates to monoclonal antibodies that neutralize heparanase, along with pharmaceutical compositions that include these antibodies. The applications of her invention extend to treating diseases such as cancer, inflammation, diabetes, and related complications. Furthermore, her invention encompasses combined therapies that integrate the heparanase-neutralizing antibodies with anti-cancer treatments like chemotherapy or radiation.
Career Highlights
Throughout her career, Marina has worked with notable organizations, including Technion Research & Development Foundation Limited and Hadasit Medical Research Services and Development Ltd. Her innovative research has positioned her as a key figure in the field of therapeutic antibody development.
Collaborations
Marina has collaborated with esteemed colleagues, including Israel Vlodavsky and Neta Ilan. These partnerships have furthered her research and contributed to the advancement of her inventions.
Conclusion
Marina Weissmann's work in developing heparanase-neutralizing monoclonal antibodies showcases her dedication to addressing critical health challenges. Her contributions to biomedical research are invaluable and continue to pave the way for innovative treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile